Dose-dependent Differential Activation of AKT Induced by Progesterone in Human Breast Cancer Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The dose-dependent effect of progesterone on PI3K/AKT signaling pathway, which plays a vital role in regulating various biological processes in human breast cancer, is not well defined. Herein, we analyzed the dose-associated influence of progesterone on AKT activation in human breast cancer cells. MCF-7 cells were treated with progesterone at a concentration ranging from 10-10 M through 10-6 M for 30 minutes and the extent of AKT phosphorylation was assessed using western blotting. Treatment with progesterone at various concentrations led to AKT phosphorylation in these cells. Notably, AKT activation, when treated with lower doses of progesterone was higher than that observed upon treatment with higher doses. Pre-treatment with PI3K inhibitor (LY294002) attenuated progesterone-induced AKT activation in a parallel manner over the range of progesterone doses administered. RU486, which is a progesterone receptor antagonist, induced AKT phosphorylation. These results suggest that progesterone seems to induce dose-dependent differential activation of PI3K/AKT pathway in MCF-7 cells.
Abstract
The dose-dependent effect of progesterone on PI3K/AKT signaling pathway, which plays a vital role in regulating various biological processes in human breast cancer, is not well defined. Herein, we analyzed the dose-associated influence of progesterone on AKT activation in human breast cancer cells. MCF-7 cells were treated with progesterone at a concentration ranging from 10-10 M through 10-6 M for 30 minutes and the extent of AKT phosphorylation was assessed using western blotting. Treatment with progesterone at various concentrations led to AKT phosphorylation in these cells. Notably, AKT activation, when treated with lower doses of progesterone was higher than that observed upon treatment with higher doses. Pre-treatment with PI3K inhibitor (LY294002) attenuated progesterone-induced AKT activation in a parallel manner over the range of progesterone doses administered. RU486, which is a progesterone receptor antagonist, induced AKT phosphorylation. These results suggest that progesterone seems to induce dose-dependent differential activation of PI3K/AKT pathway in MCF-7 cells.
참고문헌 (32)
- Druckmann R, "Progestins and their effects on the breast", Maturitas, 4646S1, pp.59~69 (2003)
- Kurebayashi J, "Resistance to endocrine therapy in breast cancer", Cancer Chemother Pharmacol, 56(1), pp.39~46 (2005)
- Trabert B, "Progesterone and breast cancer", Endocr Rev, 41, pp.320~344 (2020)
- Trayes KP, "Breast cancer treatment", Am Fam Physician, 104, pp.171~178 (2021)
- Seeger H, "Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells", J Br Menopause Soc, 9, pp.36~38 (2003)
- Alkhalaf M, "Overexpression of wild-type p53gene renders MCF-7 breast cancer cells more sensitive to the antiproliferative effect of progesterone", J Endocrinol, 179, pp.55~62 (2003)
- Jeng MH, "Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation", Cancer Res, 52, pp.6539~6546 (1992)
- Catherino WH, "Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism", Br J Cancer, 67, pp.945~952 (1993)
- Schatz RW, "Effects of interaction between estradiol-17 beta and progesterone on the proliferation of cloned breast tumor cells(MCF-7 and T47D)", J Cell Physiol, 124, pp.386~390 (1985)
- Formby B, "Bcl-2, survivin and variant CD44 v7-v10are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis", Mol Cell Biochem, 202, pp.53~61 (1999)
- Moore MR, "Progestin inhibition of cell death in human breast cancer cell lines", J Steroid Biochem Mol Biol, 98, pp.218~227 (2006)
- Cantley LC, "The phosphoinositide 3-kinase pathway", Science, 296, pp.1655~1657 (2002)
- Coffer PJ, "Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3- kinase activation", Biochem J, 335, pp.1~13 (1998)
- Tokunaga E, "Activation of PI3K", Akt signaling and hormone resistance in breast cancer, 2006, pp.13, 137~144
- Noorolyai S, "The relation between PI3K", AKT signalling pathway and cancer, 2019, pp.698, 120~128
- Morgensztern D, "PI3K", Akt, Anticancer Drugs, pp.2005, 16[DOI]
- Liu W, "Roles of AKT signal in breast cancer", Front Biosci, 12, pp.4011~4019 (2007)
- Ingrid A, "The PI3K", AKT pathway as a target for cancer treatment, 2016, pp.67, 11~28
- Lim YC, "Endoxifen(4-hydroxy-N-desmethyl-tamoxifen)has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen", Cancer Chemother Pharmacol, 55, pp.471~478 (2005)
- Butts CL, "Progesterone inhibits mature rat dendritic cells in a receptor-mediated fashion", Int Immunol, 19, pp.287~296 (2007)
- Ballaré C, "Progesterone signaling in breast and endometrium", J Steroid Biochem Mol Biol, 102, pp.2~10 (2006)
- Leonhardt A, "Progesterone receptor transcription signaling mechanisms", Steroids, 68, pp.761~770 (2003)
- Vallejo G, "Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cells", Mol Endocrinol, 19, pp.3023~3037 (2005)
- Vanhaesebroeck B, "Synthesis and function of 3-phosphorylated inositol lipids", Annu Rev Biochem, 70, pp.535~602 (2001)
- Lange CA, "Integration of progesterone receptor action with rapid signaling events in breast cancer models", J Steroid Biochem Mol Biol, 108, pp.203~212 (2008)
- Richer JK, "Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells", J Biol Chem, 277, pp.5209~5218 (2002)
- Mulac-Jericevic B, "Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform", Proc Natl Acad Sci U S A, 100, pp.9744~9749 (2003)
- Schwertschlag US, "Phase 1 pharmacokinetics (PK), and pharmacodynamics(PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumors", J Clin Oncol, 26, pp.14532~14532 (2008)
- Focan C, "Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial", Br J Cancer, 85, pp.1~8 (2001)
- Muss HB, "High-dose progestin therapy for metastatic breast cancer", Ann Oncol (1992)
- Haller DG, "Progestational agents in advanced breast cancer : an overview", Semin Oncol, 13, pp.2~8 (1986)
- Zaucha R, "Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate", Breast, 13, pp.321~324 (2004)